Full-Time

Scientist I

Immunohistochemistry

Confirmed live in the last 24 hours

ArsenalBio

ArsenalBio

201-500 employees

Develops programmable cell therapies for cancer

Biotechnology
Healthcare

Compensation Overview

$110.2k - $135kAnnually

Junior, Mid

San Bruno, CA, USA

Category
Biology Lab & Research
Biology & Biotech

You match the following ArsenalBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor's degree in Biology, Biochemistry, Cell Biology, and/or relevant histopathology-related degree with 7+ years of relevant experience; OR Masters with 5+ years relevant experience; OR PhD with 0-2+ years relevant experience
  • 5+ years of experience in histology laboratory sciences
  • Robust experience and expertise in multiplex immunofluorescence assay (mIF) design, execution, scanning, and interpretation using digital pathology software
  • Knowledge of basic histological features of normal tissues and cancer, with demonstrated ability to score intensity and percentage of staining
  • Ability to adapt quickly, learn new skills, and think creatively to address evolving research priorities
  • Proven ability to collaborate, manage multiple projects to meet deadlines, and take on additional responsibilities as needed
  • Strong organizational skills, record-keeping and interpersonal communication skills (verbal and written) required
Responsibilities
  • Independently design and execute cell- and tissue-based multiplex immunofluorescence and in-situ hybridization assays
  • Perform cell- and tissue-based staining and image analysis to characterize target expression and on- and off-target binding in various organs and tissues
  • Summarize staining profiles of routine and novel biomarkers in human and animal model tissues and present findings to colleagues
  • Execute and assist in developing standard operating procedures, including staining procedures, special stains, and exploratory assays
  • Organize detailed methods, results, and data in an electronic lab notebook
  • Work collaboratively in matrix organizations via the contribution of data, ideas, and presentations
  • Manage and communicate with CROs contracted to support validation and exploratory studies
  • Assist in teaching and guiding research associates and scientists in histological and immunohistochemical techniques
  • Assist in the maintenance of histology equipment including but not limited to microscopes, autostainers, and microtomes
Desired Qualifications
  • Experience working in GLP, GCP, and CLIA-compliant environments and/or experience with GC/LP and CLIA regulatory standards for immunohistochemistry assay development
  • Experience in companion and complementary diagnostics for clinical evaluation

ArsenalBio focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Unlike many competitors, ArsenalBio emphasizes a diverse team of experts from various scientific and clinical backgrounds, which aids in their goal of creating effective cancer treatments. Their ultimate aim is to provide innovative therapies that can significantly improve outcomes for patients suffering from solid tumor cancers.

Company Size

201-500

Company Stage

Series C

Total Funding

$612.8M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
  • Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
  • Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.

What critics are saying

  • Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
  • High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
  • Regulatory scrutiny on gene-editing technologies could delay therapy approvals.

What makes ArsenalBio unique

  • ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
  • Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
  • ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-1%

2 year growth

16%
Arsenal Bio
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

BioPharma Reporter
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Bio
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.